INTANGIBLE ASSETS AND GOODWILL (Tables)

9 Months Ended

Sep. 30, 2011

INTANGIBLE ASSETS AND GOODWILL

Schedule of components of intangible assets

			As of September 30, 2011							As of December 31, 2010
			Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite-lived intangible assets:
	Product brands		$	4,898,410	$	(620,638	)	$	4,277,772	$	4,227,465	$	(404,951	)	$	3,822,514
	Corporate brands			178,906		(8,420	)		170,486		169,675		(2,191	)		167,484
	Product rights			918,698		(278,360	)		640,338		1,074,611		(279,275	)		795,336
	Partner relationships			138,219		(13,710	)		124,509		—		—			—
	Out-licensed technology and other			225,741		(45,254	)		180,487		205,332		(17,842	)		187,490
		Total finite-lived intangible assets		6,359,974		(966,382	)		5,393,592		5,677,083		(704,259	)		4,972,824
Indefinite-lived intangible assets:
	Acquired IPR&D			1,439,106		—			1,439,106		1,399,956		—			1,399,956
			$	7,799,080	$	(966,382	)	$	6,832,698	$	7,077,039	$	(704,259	)	$	6,372,780

Schedule of amortization expense related to intangible assets

	Three Months Ended September 30				Nine Months Ended September 30
	2011		2010		2011		2010
Alliance and royalty revenue	$	268	$	268	$	804	$	804
Cost of goods sold		2,026		2,026		6,077		6,077
Amortization expense		138,027		35,499		365,016		102,098
	$	140,321	$	37,793	$	371,897	$	108,979

Schedule of estimated aggregate amortization expense for each of the five succeeding years

	2011		2012		2013		2014		2015
Amortization expense	$	504,586	$	558,287	$	555,724	$	547,238	$	533,910

Schedule of changes in the carrying amount of goodwill

	U.S. Neurology and Other		U.S. Dermatology			Canada and Australia			Branded Generics — Europe			Branded Generics — Latin America			Total
Balance, January 1, 2011	$	1,379,516	$	498,508		$	394,787		$	352,736		$	375,829		$	3,001,376
Additions(a)		—		—			5,388			366,443			—			371,831
Adjustments(b)		187,248		(338	)		(32,963	)		(24,623	)		(12,858	)		116,466
Foreign exchange and other		—		—			(22,130	)		(40,429	)		(47,977	)		(110,536	)
Balance, September 30, 2011	$	1,566,764	$	498,170		$	345,082		$	654,127		$	314,994		$	3,379,137

(a)

Relates to the acquisitions of PharmaSwiss, Sanitas and Ganehill (as described in note 3).

(b)

Reflects the impact of measurement period adjustments related to the Merger (as described in note 3).